This 187-page report, “Global Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Region: COVID-19 Impact and Growth Opportunity,” is highlighted by 85 tables and 84 figures and is based on an in-depth analysis of the entire global preventive vaccines market and all of its sub-segments. Premium primary and secondary information sources are used to create in-depth research and evaluation, with input coming from business specialists working throughout the value chain.
Due to rising healthcare costs, new vaccine developments, and a growing demand for preventive vaccinations, particularly the newly developed COVID-19 vaccines, the global market for preventive vaccines will reach $80.47 billion by 2026, expanding by 10.81% annually during 2020–2026.
The study uses 2019 as the foundation year for forecasts from 2020 to 2026 and is based on research from 2016 to 2019. (Please note that the report will be updated before to delivery to ensure that the forecast includes at least 5 years beyond the base year and the most recent historical year serves as the base year.)
Request Research Sample with Latest Industry Insights: https://altusmarketresearch.com/reports/sample/3464
The following elements are identified and examined in-depth qualitative analyses:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
By taking COVID-19 into consideration, the trend and prognosis for the global market are predicted with an upbeat, fair-minded, and cautious viewpoint. The worldwide market for preventive vaccinations is quantified from the viewpoints of vaccine type, disease, administration, patient, and region using the balanced (most likely) projection.
The worldwide market is divided into the following sub-markets based on vaccine type, with annual revenue ($ mn) for 2016–2026 given in each area.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• Recombinant Vector Vaccines
• Other Vaccines
Based on Disease, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Vaccines for Pneumococcal Disease
• Vaccines for Poliovirus
• Vaccines for Hepatitis
• Vaccines for Influenza
• Vaccines for Measles, Mumps, and Rubella (MMR)
• Vaccines for Varicella
• Vaccines for Human Papilloma Virus
• Vaccines for COVID-19
• Vaccines for Other Diseases
Based on Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes
Based on Patient, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
Pediatric Vaccines
• Pneumococcal
• Measles, Mumps, and Rubella (MMR)
• Varicella
• Hepatitis
• Poliovirus
• Haemophilus Influenzae B (HIB)
• Other Diseases
Adult Vaccines
• Influenza
• Cervical Cancer
• Hepatitis
• Zoster
• Other Diseases
Along with the above national/local markets, the following geographic areas are thoroughly investigated:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
In Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
• America, North (U.S., Canada, and Mexico)
Latin America (Brazil, Columbia, Argentina, Rest of South America)
• MEA (Saudi Arabia, UAE, Egypt)
Detailed analysis and statistics for yearly revenue ($ mn) for each area and important nation are accessible for the years 2016 through 2026. All regional markets are broken down by country, and major national markets are divided across the predicted years based on vaccine type, disease, and route of administration.
The study also analyses the present competition landscape, the anticipated trend, and it provides profiles of major suppliers, including both established market leaders and significant up-and-coming companies.
Through AMR’s Risk Assessment System, possible risks related to investing in the worldwide market for preventive vaccinations are evaluated quantitatively and qualitatively. Critical Success Factors (CSFs) are developed based on the risk analysis and assessment as a guide to assist investors and shareholders in identifying new possibilities, managing and minimising risks, developing suitable business models, and making informed strategies and choices.
Key Players (this list may not be exhaustive; other businesses may be included upon request):
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline PLC
Johnson & Johnson
Merck & Co.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd
